Exciting news from NovaCina!
We’ve installed and qualified a new Cytiva SA25 GMP isolator filling line to support small- and medium-batch sizes for all clinical phases—vials, syringes and cartridges. Since acquiring the manufacturing plant from Pfizer in April 2023, we have invested heavily into the site growing diverse CDMO capability and team. And now we’ve added another 5 million units of clinical filling capacity!
Just a reminder: R&D activities in Australia are eligible for up to 48.5% cash back. Contact us today to learn more about how to fill your clinical development plan!
Check out the full article to learn more about this significant development!
#NovaCina #CDMO #ClinicalSupplies #PerthExpansion